Stock Alert: Calithera Biosciences Tanks 40%

Shares of Calithera Biosciences, Inc. (CALA) are currently slipping over 40% after the company said its trial of Telaglenastat in renal cell carcinoma did not achieve primary endpoint.

CALA is currently trading at $2.89, down $2.02 or 41.04%, on the Nasdaq.

The clinical-stage biotechnology company focused on developing small-molecule drugs for the treatment of cancer, announced topline results from the CANTATA clinical study of its glutaminase inhibitor telaglenastat in patients with advanced or metastatic renal cell carcinoma.

As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival in the study population.

"We are disappointed that the CANTATA trial did not achieve its primary endpoint, particularly on behalf of the people living with advanced RCC, many of whom could benefit from additional treatment options with novel mechanisms of action to address this difficult-to-treat disease," said Susan Molineaux, PhD, president and chief executive officer of Calithera.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...
Follow RTT